Novel Drug Rytvela Shows Promise Against Premature Birth in Preclinical Study

New research indicates that Rytvela, an anti-inflammatory drug candidate, reduced premature birth and infant mortality when administered after the onset of preterm labor in a preclinical mouse model. This promising development stands in contrast to the current standard treatment for preterm labor, Nifedipine, which did not demonstrate similar benefits in this study.

The preclinical data, published in The Journal of Immunology, showed Rytvela decreased rates of preterm birth by 40%, which extended gestation and fetal development. Rytvela also prevented inflammation-induced neonatal tissue injury and promoted neonatal development, even when administered following inflammation exposure.

"Rytvela represents a potential treatment approach to prolong pregnancy and fetal growth safely, allowing for newborn organ development in utero." - A neonatologist involved in the study.

Targeting Inflammation, Preserving Immunity

Inflammation in the uterus and placenta is a significant factor in preterm labor, often initiating a series of inflammatory signals. Rytvela targets the actions of a specific pro-inflammatory signal, IL-1ß, to decrease inflammation.

Crucially, unlike existing IL-1ß-targeting drugs, Rytvela avoids immune suppression, preserving the immune system.

The lead author of the study noted that the intent behind developing Rytvela was to allow greater fetal maturation before birth while suppressing harmful inflammation, which current drugs do not achieve.

Addressing a Critical Global Health Challenge

Preterm birth is a widespread issue, affecting 13.5 million births annually and responsible for over 900,000 deaths each year. Surviving infants may experience short- and long-term complications due to undeveloped organs and systems at birth, as well as exposure to inflammation.

Existing treatments for preterm labor primarily aim to stop or slow contractions, typically delaying labor for less than 48 hours. This limited delay does not prevent preterm birth or provide sufficient time for vital fetal development.

Next Steps Towards Clinical Trials

Researchers are currently finalizing preclinical research for Rytvela and are preparing for clinical trials, holding potential for a significant impact on maternal and infant health worldwide.